Loading…
This event has ended. Create your own event on Sched.
Welcome to the Science Summit at UNGA76, a major contribution to advancing Science for the UN SDGs. Online from 14- September - 5 October 2021.
ISC will organise the second edition of the UNGA76 Science Summit around the 76th United Nations General Assembly (SSUNGA76) in September 2021. The objective of the virtual meeting will be to raise awareness of the role and contribution of science to the attainment of the United Nations Sustainable Development Goals. It will demonstrate initiatives that provide models for global science mechanisms and activities in support of the SDGs, particularly in science infrastructure and capacity building. Science is and will enable sustainable economic, environmental, and societal development. Science is more than a funding prioritisation exercise: science is impacting all areas of policy-making and is playing a more critical role in how policy objectives are achieved and the consequent benefit to people everywhere, including responses to global challenges.
Engagement with policy leadership is more important than ever: UNGA76 is a unique forum for science to demonstrate how policy and political leadership can benefit from innovation. Central to this is the role of nonstate actors and the multilateral fora, which increasingly determine how priorities are set. Science needs to be part of this dialogue and inform outputs through thought leadership, evidence, insights, analysis, and innovation.

Registration is available here.
avatar for Ruxandra Draghia-Akli

Ruxandra Draghia-Akli

Johnson & Johnson Global Public Health R&D, USA
Global Head
Ruxandra Draghia-Akli is Global Head, Johnson & Johnson Global Public Health R&D, where her and her team advance global public health into the next era of innovation through discovery, development, and technology capabilities. She accelerates GPH’s end-to-end strategy by collaborating with teams across Johnson & Johnson on assets with application in global public health settings. Under her leadership, GPH R&D adds value and generates new external innovation opportunities through our J&J Discovery Centers and partners.

Ruxandra is a cross-sector leader with experience in industry, government, and academia. She led Medical and Scientific Affairs for vaccines at Merck, and she worked for the European Commission, first as Director and later as Deputy Director-General, overseeing programmatic, legislative, and research and innovation issues, while contributing to the Commission’s strategy for improving public health.

Ruxandra holds an M.D. from Carol Davila University, Romania, and a PhD in human genetics from the Romanian Academy of Medical Sciences. She undertook doctoral training at University Rene Descartes in Paris, France and postdoctoral training at Baylor College of Medicine, Houston, Texas, with a focus on molecular biology, gene therapy and novel vaccines. Ruxandra has authored and co-authored more than 100 papers and holds over 100 patents.